Rising Patent-Cliff Exposure & CMS Drug Spending Portfolio

Rising (US): 20 reconciled FDA prescription therapies, $50.6M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies20
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$50.6M
2024 Medicare Part D Spend$36.2M
2024 Medicaid Spend$14.4M
California HCAI SB 17 Filings2 WAC filings (max 122.2% 2-yr change)